By virtue of investment in Celladon, a number of pharmaceutical companies have a front row seat to evaluate the significance of CUPID 2. We anticipate a licensing or a merger and acquisition (M&A) transation, if results are promising for future success
Health Medicine NetworkUp to Fve CAR-Ts Are Now Excepted To Enter The Clinic in 2015
The Fly On The Wall
"We are impressed with the magnitude of the beat and the breadth of the strength that CyberArk saw across all key verticals. The threat landscape remains elevated and CyberArk's solutions are increasingly strategic to such enterprises, we see accelerated revenues to continue. Oppenheimer said
Mad Money Remix
CyberArk to run higher, CEO's willing to pay whatever it takes to protect their co's
Zacks CYBR Beats Big . CYBR in $70 Billion Market
CYBR Strong Fourth Quarter and Full Year 2014 Results- Worldwide spending on IT security in 2014 was about $70 billion.
any other factors?
CyberArk Software, Ltd. (NASDAQ:CYBR)The IDC MarketScape assesses vendors offering products in the privileged access administration (PAM) market and notes that, “CyberArk is the “big gorilla” with the most proceed and largest customer base.
Piper Jaffray has opined that both GoPro Inc. (NASDAQ: GPRO) and Nike Inc. (NYSE: NKE) have plentyof room to run. The firm has issued price targets with strong double-digit upside.
Why Agenus Inc. Shares Surged Higher
By Todd Campbell | More Articles
April 28, 2015 | Comments (0)
Today, results from GlaxoSmithKline's phase 3 study of this vaccine show that it protects 98% of people age 70 or older and 97% of people over age 50. Overall, more than 16,000 people were studied in the trial.
The vast majority of adults over age 50 are at risk of reactivating the virus responsible for causing shingles and its painful symptoms
you beat me to it, I will post on Stocktwits now.
Sentiment: Strong Buy
ADXS and Merck